A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer

Authors

  • Ravinder Clayton Tom Baker Cancer Centre Calgary, AB
  • Jackson Wu Tom Baker Cancer Centre Calgary, AB
  • Daniel Y Heng Tom Baker Cancer Centre Calgary, AB
  • Scott A North Cross Cancer Institute Edmonton, AB
  • Urban Emmenegger Odette Cancer Centre Toronto, ON
  • Sebastien Hotte Juravinski Cancer Centre Hamilton, ON
  • Kim Chi BC Cancer Agency Vancouver, BC
  • Rob Zielinski BC Cancer Agency Vancouver, BC
  • Humaid Al-Shamsi Juravinski Cancer Centre Hamilton, ON
  • Leo Chen BC Cancer Agency Vancouver, BC
  • Bernhard Eigl BC Cancer Agency Vancouver, BC

DOI:

https://doi.org/10.5489/cuaj.1891

Keywords:

Abiraterone, Prostate Cancer

Abstract

Introducton: The COU-AA-301 trial showed that abiraterone acetate (abiraterone), an oral cytochrome p450 CYP17 inhibitor, improved survival for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel. To better understand the non-clinical trial experience with abiraterone, we undertook a multicentre retrospective analysis of Canadian mCRPC patients treated with abiraterone.

Methods: Consecutive patients with mCRPC who received abiraterone post-docetaxel were identified using centralized pharmacy records. These patients came from 5 Canadian tertiary cancer centres. Patients who received abiraterone for approved indications were included. Demographics, prognostic factors, treatment outcomes and adverse events were abstracted.

Results: We included 187 patients who initiated abiraterone between January 2011 and June 2012. The median age at diagnosis and abiraterone start was 65 and 73 years, respectively. Seventy-three (39%) patients had metastatic disease at diagnosis. The Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 and 3 was noted in 17, 96, 39 and 8 patients, respectively. The median prostate-specific antigen (PSA) at abiraterone start was 132, with a median PSA doubling time of 2.8 months. The median follow-up of patients still on active follow-up was 13 months. The proportion of patients achieving a ≥50% PSA reduction was 64/177 (36%). PSA progression-free survival was 3.5 months (95% confidence interval [CI], 3.0, 4.0). Median overall survival from start of abiraterone was 11 months (95% CI, 8.0, 13) and 38 months (95% CI, 31, 41) from date of mCRPC. Anemia and fatigue were the most commonly reported adverse events.

Conclusions: This study carries the inherent limitations of a retrospective chart review. The outcomes in this series of men treated with abiraterone in a non-trial setting were expected, considering previous clinical trials. Our results, therefore, support the generalizability of the COU-AA-301 study results.

Downloads

Download data is not yet available.

Downloads

Published

2014-09-09

How to Cite

Clayton, R., Wu, J., Heng, D. Y., North, S. A., Emmenegger, U., Hotte, S., Chi, K., Zielinski, R., Al-Shamsi, H., Chen, L., & Eigl, B. (2014). A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. Canadian Urological Association Journal, 8(9-10), e583–90. https://doi.org/10.5489/cuaj.1891

Issue

Vol. 8 No. 9-10 (2014): CUAJ September

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.